Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer

Journal of the National Cancer Institute

Volumn 103, Issue 4, 2011, Pages 347-351

  Fruscio, Robert ^a   Garbi, Annalisa ^a   Parma, Gabriella ^b   Lissoni, Andrea Alberto ^a   Garavaglia, Daniela ^c   Bonazzi, Cristina Maria ^a   Dell'Anna, Tiziana ^a   Mangioni, Costantino ^a   Milani, Rodolfo ^a   Colombo, Nicoletta ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHI SQUARE TEST; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79951909015     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq530     Document Type: Article

References (26)

1. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281-1287.
2. Thatcher N, Girling DJ, Hopwood P, et al. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose intensity of chemotherapy with granulocyte colony stimulating factors support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol. 2000;18(2):395-404. (Pubitemid 30056430)
3. Woll PJ, Hodgetts J, Lomax L, et al. Can cytotoxic dose intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol. 1995;13(3):652-659.
4. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-1211. (Pubitemid 28407086)
5. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodepositive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439. (Pubitemid 46594092)
6. Ozols RF. Ovarian cancer: is dose intensity dead? J Clin Oncol. 2007;25(27):4157-4158.
7. Möbus V, Wandt H, Frickhofen N, et al. High-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first line treatment of advanced ovarian cancer: results of a phase III intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25(27):4187-4193. (Pubitemid 47548557)
8. Katsumata N, Yasuda M, Takahashi F, et al; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, openlabel, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214. (Pubitemid 11167383)
10. Bernstein D, Lagakos SW. Sample size and power determination for stratified clinical trials. J Stat Comput Simul. 1978;8(1):65-73.
11. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature. 1976;264(5586):542-545.
12. Torri V, Korn EL, Simon R. Dose intensity analysis in advanced ovarian cancer patients. Br J Cancer. 1993;67(1):190-197. (Pubitemid 23034947)
13. Ngan HY, Choo YC, Cheung M, et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy. 1989;35(3):221-227.
14. Palmer MC, Shepert E, Schepansky A, MacLean GD. Novel, dose intensive, singleagent cisplatin in the first-line management of advanced stage ovarian cancer. Int J Gynecol Cancer. 1992;2(6):301-306.
15. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13(7):1589-1599.
16. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol. 1996;14(7):2113-2119. (Pubitemid 26230114)
17. Conte PF, Bruzzone M, Carnino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol. 1996;14(2):351-356. (Pubitemid 26050994)
18. Wrigley E, Weaver A, Jayson G, et al. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Ann Oncol. 1996;7(7):705-711. (Pubitemid 26323543)
19. Bolis G, Favalli G, Danese S, et al. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol. 1997;15(5):1938-1944. (Pubitemid 27209524)
20. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol. 1997;15(1):193-198. (Pubitemid 27020573)
21. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol. 1998;16(7):2426-2434. (Pubitemid 28309037)
22. Cocconi G, Bella M, Lottici R, et al. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma. Am J Clin Oncol. 1999;22(6):559-567. (Pubitemid 30266053)
23. Joly F, Héron JF, Kerbrat P, et al. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol. 2000;78(3, pt 1):361-368.
24. Dittrich Ch, Sevelda P, Salzer H, et al.; Austrian Ovarian Cancer Study Group. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer. 2003;39(8):1129-1140. (Pubitemid 36555871)
25. Leunen K, Cadron I, Van Gorp T, et al. Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Int J Gynecol Cancer. 2009;19(9):1501-1504.
26. Gabra H. Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: teaching old dogs new tricks? Discov Med. 2009;8(42):140-144.